Ftse Mib
33.766,29
-0,06%
DAX
19.884,75
-0,57%
S&P 500
5.930,85
1,09%
NASDAQ
19.572,60
1,03%
Bitcoin
97.153,40
-0,05%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Genprex Inc (GNPX) Genprex Inc (GNPX) Notizie

Genprex Inc

GNPX
0,91
0,01 (1,11%)
21 Dic 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
20/12/202414:45EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
16/12/202415:15EDGAR2Form 8-K - Current report
16/12/202415:15PRNUSGenprex Receives Safety Review Committee Approval to Advance..
06/12/202423:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202423:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202423:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202423:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/11/202415:29EDGAR2Form 8-K - Current report
20/11/202415:29PRNUSGenprex Signs Exclusive License to Additional Gene Therapy..
19/11/202423:15EDGAR2Form 8-K - Current report
13/11/202415:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202423:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/11/202415:29EDGAR2Form 8-K - Current report
05/11/202415:29PRNUSGenprex Collaborators Present Positive Preclinical Data on..
31/10/202414:29PRNUSGenprex to Participate in 2024 BIO Europe Conference
28/10/202414:29PRNUSGenprex Collaborators Present Positive Preclinical Data on..
24/10/202418:23EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
24/10/202415:29EDGAR2Form 8-K - Current report
24/10/202415:29PRNUSGenprex Announces Sponsored Research Agreement with The..
22/10/202418:01EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
15/10/202415:29EDGAR2Form 8-K - Current report
15/10/202415:29PRNUSGenprex Receives Safety Review Committee Approval to Advance..
10/10/202415:29PRNUSGenprex Collaborators to Present Positive Preclinical Data..
07/10/202415:29PRNUSGenprex Collaborators to Present Positive Preclinical Data..
26/9/202423:15EDGAR2Form 8-K - Current report
23/9/202415:29PRNUSGenprex Featured in CEO/CFO Magazine Discussing Novel Gene..
19/9/202415:29PRNUSGenprex Announces Formation of Mesothelioma Clinical..
09/9/202415:29PRNUSGenprex Collaborators to Present Positive Preclinical Data..
04/9/202415:30EDGAR2Form 8-K - Current report
04/9/202415:29PRNUSGenprex Announces Plans to Launch Separate Company to Focus..
03/9/202414:15PRNUSGenprex to Present and Participate at Upcoming September..
16/8/202422:18EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
15/8/202415:30PRNUSGenprex Releases New Video Featuring Chief Medical Officer..
14/8/202415:25PRNUSGenprex Announces Positive Clinical Study Updates from..
13/8/202414:38EDGAR2Form 8-K - Current report
13/8/202414:31PRNUSGenprex Granted Patent in Singapore for Reqorsa® Gene..
09/8/202422:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202414:30PRNUSGenprex to Present at the August Sidoti Microcap Conference
27/6/202414:31PRNUSGenprex Issues Stockholder Letter and Provides 2024..
30/5/202414:31PRNUSGenprex to Present at the 2024 BIO International Convention
20/5/202422:35EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
15/5/202422:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/5/202414:31PRNUSGenprex Doses First Patient in Acclaim-3 Clinical Study of..
13/5/202414:31PRNUSGenprex Announces the Appointment of Jose A. Moreno Toscano..
09/5/202414:11EDGAR2Form 8-K - Current report
09/5/202400:08PRNUSGenprex Announces the Passing of its Co-Founder and Chief..
01/5/202414:31PRNUSGenprex to Present and Participate at Upcoming May Investor..
09/4/202414:31PRNUSGenprex Collaborators Report Positive Preclinical Data on..
03/4/202414:31PRNUSGenprex Expands Clinical Trial Sites for Acclaim-3 Clinical..
02/4/202414:31PRNUSGenprex Collaborators Publish Positive Preclinical Data with..
Apertura: 0,8701 Min: 0,8578 Max: 0,9617
Chiusura: 0,90

La tua Cronologia

NASDAQ
GNPX
Genprex
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network